Phase 1/2 Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of the Oral EGFR/HER2 Inhibitor AP32788 in Non-Small Cell Lung Cancer

Trial Profile

Phase 1/2 Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of the Oral EGFR/HER2 Inhibitor AP32788 in Non-Small Cell Lung Cancer

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 08 Sep 2017

At a glance

  • Drugs AP 32788 (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors ARIAD Pharmaceuticals
  • Most Recent Events

    • 07 Nov 2016 According to an ARIAD Pharmaceutical media release, data from this trial are expected in 2017.
    • 22 Apr 2016 Status changed from not yet recruiting to recruiting.
    • 23 Feb 2016 According to an ARIAD Pharmaceuticals media release, status changed from planning to not yet recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top